Institute of Pharmaceutical Sciences, Department of Pharmaceutical Technology and Biopharmacy, University of Freiburg, Sonnenstrasse 5, 79104, Freiburg, Germany.
Institute of Pharmaceutical Sciences, Department of Pharmaceutical Technology and Biopharmacy, University of Freiburg, Sonnenstrasse 5, 79104, Freiburg, Germany.
J Pharm Biomed Anal. 2021 Jul 15;201:114120. doi: 10.1016/j.jpba.2021.114120. Epub 2021 May 5.
In recent decades liposomes have become attractive carriers for hydrophobic drugs to enhance their solubility and improve their therapeutic application. For liposomal drug products, both drug and lipid quantification are required by regulatory authorities, making the implementation of precise quantification methods a step of crucial importance in formulation development and quality control. Therefore, the present study is focused on the development and validation of a simple and time-saving method for the simultaneous analysis of hydrophobic drugs and conventional liposomal components. The new HPLC method was established with a combined detection by a diode array detector (DAD) and a corona charged aerosol detector (CAD). As a wide calibration range of the liposomal components can be achieved (10-1000 μg/mL), the analysis of samples with different drug to lipid ratios is enabled. Moreover, an excellent precision including repeatability and low limits of detection (≤ 1.8 μg/mL) and limits of quantification (≤ 5.9 μg/mL) were accomplished for all analytes. The method was successfully applied to liposomes incorporating mitotane. Everolimus was additionally analyzed as hydrophobic model drug. Furthermore, cyclodextrin/mitotane inclusion complexes were investigated to proof a broad range of applications for the developed method.
近几十年来,脂质体已成为提高疏水性药物溶解度和改善其治疗应用的有吸引力的载体。对于脂质体药物产品,监管机构都需要对药物和脂质进行定量,这使得实施精确的定量方法成为制剂开发和质量控制中至关重要的一步。因此,本研究专注于开发和验证一种简单且节省时间的方法,用于同时分析疏水性药物和常规脂质体成分。该新的 HPLC 方法是通过二极管阵列检测器(DAD)和电晕荷电气溶胶检测器(CAD)的组合检测来建立的。由于可以实现脂质体成分的宽校准范围(10-1000μg/mL),因此可以分析具有不同药物与脂质比的样品。此外,对于所有分析物,均实现了出色的精密度,包括重复性和低检测限(≤1.8μg/mL)和定量限(≤5.9μg/mL)。该方法成功应用于包封米托坦的脂质体。此外,还分析了作为疏水性模型药物的依维莫司。此外,还研究了环糊精/米托坦包合物,以证明所开发方法具有广泛的应用范围。